Inactive Instrument
IRLAB Therapeutics AB Stock Nasdaq Stockholm
Stocks
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Nasdaq Stockholm
|
||
| - SEK | - |
|
| 10-27 | Irlab Therapeutics Set to Obtain US Patent for Parkinson's Disease Drug Candidate | MT |
| 10-27 | Irlab receives positive patent notice in the US for IRL1117 | FW |
| Market Cap | 309M 31.61M 28.22M 25.9M 23.56M 44.17M 2.99B 45.05M 125M 1.58B 119M 116M 4.99B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 309M 31.61M 28.22M 25.9M 23.56M 44.17M 2.99B 45.05M 125M 1.58B 119M 116M 4.99B | EV / Sales 2026 * |
3.06x | EV / Sales 2027 * | 2.16x |
| Free-Float |
83.4% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Clas Sonesson
CTO | Chief Tech/Sci/R&D Officer | 65 | 2015-12-31 |
Susanna Waters
PRN | Corporate Officer/Principal | 60 | 2012-12-31 |
| Chief Executive Officer | 63 | 2024-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Rein Piir
BRD | Director/Board Member | 68 | 2015-12-31 |
| Chairman | 73 | 2020-05-06 | |
Veronica Wallin
BRD | Director/Board Member | 40 | 2022-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.46% | +10.31% | +63.52% | +143.15% | 1,257B | |
| -0.97% | +1.60% | +43.25% | +80.09% | 651B | |
| -2.05% | +0.73% | +32.47% | +101.62% | 510B | |
| -0.23% | -0.80% | +52.52% | +66.83% | 388B | |
| -0.78% | +5.51% | +72.55% | +44.25% | 366B | |
| +0.75% | +2.98% | +33.29% | +59.13% | 303B | |
| +0.50% | +8.17% | +12.18% | +35.05% | 288B | |
| -0.12% | +4.68% | +55.97% | +74.59% | 252B | |
| -0.21% | +7.34% | +42.19% | +109.69% | 211B | |
| Average | -0.31% | +4.59% | +45.33% | +79.38% | 469.63B | |
| Weighted average by Cap. | -0.35% | +5.30% | +49.23% | +93.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 101M 10.34M 9.23M 8.47M 7.71M 14.45M 979M 14.74M 40.79M 517M 38.81M 37.99M 1.63B | 143M 14.63M 13.07M 11.99M 10.91M 20.45M 1.39B 20.85M 57.72M 731M 54.92M 53.75M 2.31B |
| Net income | -36.1M -3.69M -3.29M -3.02M -2.75M -5.15M -349M -5.26M -14.55M -184M -13.85M -13.55M -582M | 34.6M 3.54M 3.16M 2.9M 2.64M 4.94M 335M 5.04M 13.95M 177M 13.27M 12.99M 558M |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
Calendar
Select your edition
All financial news and data tailored to specific country editions
